This edition of the North America Pharmaceutical & Healthcare Newsletter includes:

• Walking a Fine Line: How to Determine When Product Innovations, Exclusive Contracts, and Bundled Discounts by a Monopolist are Illegal?
• Possible Effects of Proposed "Reverse Payment" Legislation
• The FTC's Proposed "Authorized Generic" Drug Study: Likely Impact on the Entire Industry
• Tax: Hospital Appeals District Court Determination that Medical Residents are Subject to FICA Taxation
• Intellectual Property [Patents, etc.]: What is the Standard of Obviousness?
• Environmental: It's Fall ... is it Time to Reevaluate your Environmental Compliance Management Program?
• Export Controls